GSK Egypt’s standalone profit skyrockets 3,819% YoY in Q1
Updated 5/31/2022 3:06:00 PM
Arab Finance: GlaxoSmithKline (GSK – Egypt) (BIOC) reported a 3,819% year-on-year (YoY) surge in standalone net profit for the first quarter (Q1) of 2022, according to the standalone financial statement filed to the Egyptian Exchange (EGX) on May 31st.
The company recorded a standalone net profit of EGP 870.41 million in Q1 2022, compared to EGP 22.21 million in Q1 2021.
Net sales amounted to EGP 370.17 million in the three-month period ended March 31st, up from EGP 140.04 million in the same quarter a year earlier.
GSK Egypt, a member of the British pharmaceutical company Glaxo Group, is an Egypt-based company engaged in the manufacture, packaging, marketing, sale, and distribution of pharmaceutical products.
